Inhaled Amikacin Treatment for Nontuberculous Mycobacterial Lung Disease
Stopped: Although this study was approved at the Institutional Review Board, Korea Food \& Drug Administration (KFDA) did not approve this study due to safety concern.
South Korea0Started 2012-02
Plain-language summary
The incidence of chronic pulmonary disease caused by nontuberculous mycobacteria (NTM) in human immunodeficiency virus (HIV)-negative patients has been increasing worldwide. In Korea, the common etiologic pathogens for this disease are Mycobacterium avium complex (MAC) and Mycobacterium abscessus. Treating NTM lung diseases can be extremely difficult and may require multiple drugs.
Amikacin is an effective antibiotic for NTM infection. However, intravenous amikacin treatment is limited by its systemic route of administration and a lot of adverse events. Amikacin inhalation treatment could overcome these limitations and also could be effective for treatment of NTM pulmonary disease due to maintaining a high lung concentration. The purpose of this study is to determine whether amikacin inhalation treatment is effective in patients with MAC infection who experienced treatment failure after standard treatment for more than 6 months or with M. abscessus infection.
Who can participate
Age range20 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Diagnosis of NTM lung lung disease in accordance with the 2007 ATS/IDSA criteria.
✓. MAC lung disease with persistent sputum culture positive after 6 months of standard treatment
✓. M. abscessus lung disease with persistent sputum culture positive after 6 months of standard treatment
✓. New case of M. abscessus pulmonary disease after completion of initial 4 weeks intravenous antibiotics treatment
Exclusion criteria
✕. Subjects with negative sputum culture before starting of this study
✕. Forced expiratory volume in 1 second (FEV1) \<30% of predicted at screening.
✕. Positive in HIV test.
✕. Subjects with chronic renal insufficient state (serum creatinine level is more than 2.0 mg/dL)
✕. Subjects with decreased liver function (serum total bilirubin level is more than 2 mg/dL or AST or ALT are more than 1.5 times of upper normal limits)